A phase-II clinical trial of targeted cerebral near infrared spectroscopy using standardized treatment guidelines to improve brain oxygenation in preterm infants (BOx-II): A study protocol.


Journal

Contemporary clinical trials
ISSN: 1559-2030
Titre abrégé: Contemp Clin Trials
Pays: United States
ID NLM: 101242342

Informations de publication

Date de publication:
09 2022
Historique:
received: 17 05 2022
revised: 15 07 2022
accepted: 13 08 2022
pubmed: 23 8 2022
medline: 24 9 2022
entrez: 22 8 2022
Statut: ppublish

Résumé

Mortality and brain injury are common adverse outcomes in infants born <28 weeks. Conventional pulse oximetry may not detect subclinical changes prior to deterioration and fails to detect changes within the brain. Increasing evidence supports the use of cerebral near-infrared spectroscopy (NIRS) in the early care of preterm infants, yet the impact of specific interventions on cerebral oxygenation and the relationship between cerebral hypoxia and brain injury on MRI remain to be determined. 100 infants <28 completed weeks of gestation will be recruited for a prospective, multicenter intervention trial. After informed consent, infants will undergo cerebral NIRS monitoring starting within 6 h of birth and continuing through 72 h. Infants with persistent cerebral desaturation will receive interventions following a standard treatment algorithm selected by the provider based on the patient's clinical condition. Providers will record the timing and choice of intervention(s) and term equivalent brain MRI will be performed for survivors. There are three objectives of this study: 1) to identify the relationship between cerebral hypoxia burden and brain injury on term-equivalent MRI. 2) to identify most common interventions after cerebral hypoxia, and 3) to quantify frequency of occult cerebral hypoxia events. There is increasing evidence for the role of early cerebral NIRS monitoring in the neuroprotective care of preterm infants. This phase-II trial will provide essential data to improve the intervention approach, model the effect size of interventions on a wider extent of brain injury, and quantify the discrepancy between measurements of systemic and cerebral hypoxia.

Sections du résumé

BACKGROUND
Mortality and brain injury are common adverse outcomes in infants born <28 weeks. Conventional pulse oximetry may not detect subclinical changes prior to deterioration and fails to detect changes within the brain. Increasing evidence supports the use of cerebral near-infrared spectroscopy (NIRS) in the early care of preterm infants, yet the impact of specific interventions on cerebral oxygenation and the relationship between cerebral hypoxia and brain injury on MRI remain to be determined.
METHODS/DESIGN
100 infants <28 completed weeks of gestation will be recruited for a prospective, multicenter intervention trial. After informed consent, infants will undergo cerebral NIRS monitoring starting within 6 h of birth and continuing through 72 h. Infants with persistent cerebral desaturation will receive interventions following a standard treatment algorithm selected by the provider based on the patient's clinical condition. Providers will record the timing and choice of intervention(s) and term equivalent brain MRI will be performed for survivors. There are three objectives of this study: 1) to identify the relationship between cerebral hypoxia burden and brain injury on term-equivalent MRI. 2) to identify most common interventions after cerebral hypoxia, and 3) to quantify frequency of occult cerebral hypoxia events.
DISCUSSION
There is increasing evidence for the role of early cerebral NIRS monitoring in the neuroprotective care of preterm infants. This phase-II trial will provide essential data to improve the intervention approach, model the effect size of interventions on a wider extent of brain injury, and quantify the discrepancy between measurements of systemic and cerebral hypoxia.

Identifiants

pubmed: 35995129
pii: S1551-7144(22)00212-9
doi: 10.1016/j.cct.2022.106886
pmc: PMC9489653
mid: NIHMS1832134
pii:
doi:

Substances chimiques

Oxygen S88TT14065

Banques de données

ClinicalTrials.gov
['NCT05171881']

Types de publication

Clinical Trial Protocol Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

106886

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR001085
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR003142
Pays : United States

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

J Neuroradiol. 2013 May;40(2):81-8
pubmed: 22633043
Pediatr Res. 2021 Mar;89(4):869-877
pubmed: 33038871
J Pediatr. 2017 Jul;186:9-10
pubmed: 28318530
Arch Dis Child Fetal Neonatal Ed. 2003 Jul;88(4):F275-9
pubmed: 12819157
Neonatology. 2019;116(4):356-362
pubmed: 31487704
BMJ. 2015 Jan 05;350:g7635
pubmed: 25569128
Adv Neonatal Care. 2011 Dec;11(6):382-8
pubmed: 22123468
JAMA Pediatr. 2015 Apr;169(4):332-40
pubmed: 25664703
Pediatr Res. 2022 May 5;:
pubmed: 35513716
Surg Neurol Int. 2011;2:65
pubmed: 21697979
Neonatology. 2013;104(3):171-8
pubmed: 23921600
Biomed Opt Express. 2017 Dec 05;9(1):86-101
pubmed: 29359089
Paediatr Perinat Epidemiol. 2018 Jul;32(4):380-387
pubmed: 29727020
Ophthalmology. 2009 Mar;116(3):513-8
pubmed: 19157560
Neurol Res. 2009 Jul;31(6):605-14
pubmed: 19660190
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
J Pediatr. 2020 Dec;227:94-100.e1
pubmed: 32818482
Trials. 2013 May 01;14:120
pubmed: 23782447
Pediatrics. 2000 Feb;105(2):295-310
pubmed: 10654946
Biomed Opt Express. 2016 Jul 11;7(8):2973-92
pubmed: 27570691
N Engl J Med. 2013 May 30;368(22):2094-104
pubmed: 23642047
AJNR Am J Neuroradiol. 2013 Nov-Dec;34(11):2208-14
pubmed: 23620070
Early Hum Dev. 2012 Apr;88(4):233-9
pubmed: 21924565
Front Pediatr. 2017 Mar 14;5:46
pubmed: 28352624
J Perinatol. 1995 Nov-Dec;15(6):470-9
pubmed: 8648456
J Perinatol. 2021 Apr;41(4):675-688
pubmed: 33589724
Pediatrics. 2005 Apr;115(4):990-6
pubmed: 15805375
Neonatology. 2008;94(4):237-44
pubmed: 18784420
Pediatr Res. 2016 Jan;79(1-1):55-64
pubmed: 26389823
Trials. 2019 Dec 30;20(1):811
pubmed: 31888764
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
N Engl J Med. 2010 May 27;362(21):1959-69
pubmed: 20472937
PLoS One. 2022 Jan 24;17(1):e0262640
pubmed: 35073354
Br J Ophthalmol. 2006 Nov;90(11):1378-82
pubmed: 16914473

Auteurs

Zachary Vesoulis (Z)

Washington University, St. Louis, MO, United States of America. Electronic address: vesoulis_z@wustl.edu.

Andrew Hopper (A)

Loma Linda University, Loma Linda, CA, United States of America.

Karen Fairchild (K)

University of Virginia, Charlottesville, VA, United States of America.

Santina Zanelli (S)

University of Virginia, Charlottesville, VA, United States of America.

Lina Chalak (L)

University of Texas Southwest, Dallas, TX, United States of America.

Mona Noroozi (M)

Washington University, St. Louis, MO, United States of America.

Jessica Liu (J)

Stanford University, Palo Alto, CA, United States of America.

Valerie Chock (V)

Stanford University, Palo Alto, CA, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH